

Microbiology Spectrum

A Decade-long Evaluation of Neonatal Septicaemic Escherichia coli: Clonal Lineages, Genomes and New Delhi Metallo-β-Lactamase Variants

Amrita Bhattacharjee, Kirsty Sands, Shravani Mitra, Ritojeet Basu, Bijan Saha, Olivier Clermont, Shanta Dutta, and Sulagna Basu

Corresponding Author(s): Sulagna Basu, National institute of Cholera and Enteric Diseases

Review Timeline:	Submission Date:	December 21, 2022
	Editorial Decision:	February 13, 2023
	Revision Received:	May 20, 2023
	Accepted:	May 27, 2023

Editor: Krisztina Papp-Wallace

Reviewer(s): Disclosure of reviewer identity is with reference to reviewer comments included in decision letter(s). The following individuals involved in review of your submission have agreed to reveal their identity: Jumpei Saito (Reviewer #1)

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)

DOI: https://doi.org/10.1128/spectrum.05215-22

1st Editorial Decision February 13,

20231

February 13, 2023

Dr. Sulagna Basu National institute of Cholera and Enteric Diseases Bacteriology P33, CIT Road, Scheme XM, Beliaghata Kolkata, West Bengal 700010 India

Re: Spectrum05215-22 (A Decade-long Evaluation of Neonatal Septicaemic *Escherichia coli*: Clonal Lineages, Genomes and New Delhi Metallo-β-Lactamase Variants)

Dear Dr. Sulagna Basu:

Thank you for submitting your manuscript to Microbiology Spectrum. When submitting the revised version of your paper, please provide (1) point-by-point responses to the issues raised by the reviewers as file type "Response to Reviewers," not in your cover letter, and (2) a PDF file that indicates the changes from the original submission (by highlighting or underlining the changes) as file type "Marked Up Manuscript - For Review Only". Please use this link to submit your revised manuscript - we strongly recommend that you submit your paper within the next 60 days or reach out to me. Detailed instructions on submitting your revised paper are below.

Link Not Available

Below you will find instructions from the Microbiology Spectrum editorial office and comments generated during the review.

ASM policy requires that data be available to the public upon online posting of the article, so please verify all links to sequence records, if present, and make sure that each number retrieves the full record of the data. If a new accession number is not linked or a link is broken, provide production staff with the correct URL for the record. If the accession numbers for new data are not publicly accessible before the expected online posting of the article, publication of your article may be delayed; please contact the ASM production staff immediately with the expected release date.

The ASM Journals program strives for constant improvement in our submission and publication process. Please tell us how we can improve your experience by taking this quick <u>Author Survey</u>.

Sincerely,

Krisztina Papp-Wallace

Editor, Microbiology Spectrum

Journals Department American Society for Microbiology 1752 N St., NW Washington, DC 20036 E-mail: spectrum@asmusa.org

Reviewer comments:

Reviewer #1 (Comments for the Author):

The fact that a long-term study of ExPECs was conducted on newborns admitted to the NICU is valuable information. Although the study was conducted in a single region, the content of the study was substantial, and I believe it will contribute to future research activities. On the other hand, I cannot find any evidence that the understanding of the transition of resistant strains itself will change the current practice of antimicrobial chemotherapy. In order to understand that the emergence of resistant strains is a critical situation, it is necessary to analyze the relationship between detected bacteria or isolates and outcomes (e.g., death, prolonged hospital stay, etc.). I have attached a comment on how. Please refer to the reference.

Executive Summary.

There is no information on the source of the isolates considered in this study (e.g., information about the population, geographic region, etc.).

L93 "This versatility is observed in its genome and also in its function or potential to cause disease" A reference to this statement is needed.

L106 What is "[WHO]"?

L171 "Whole genome sequencing (WGS)" WGS is spelled out in the sentence. The description of the method is redundant. It is too long compared to other items and should be shortened or moved to a supplement file.

Result.

L272 "Seventy E. coli were identified from the blood of septicaemic neonates (2009 to 2019)."

The number of cases, patient background, and outcomes (treatment outcomes) are unknown. Also, whether the results are similar to other parts of India or unique to this facility needs to be added to the discussion.

L231 "Isolates were resistant to second (52/80, 65%) and third-generation cephalosporins (67/80, 84%)" In the Methods section, the study on cephalosporins I am aware that the study regarding cephalosporins is not explicitly mentioned in the Methods section.

L267 "Transmissibility of metallo-β-lactamases and plasmid profile:" Is a colon necessary?

Discussion

L434 "under-5 mortality" The phrase "under-five" is also mentioned.

L480-489 "Several studies have shown that commensal E. coli are " The sentence is redundant due to the extensive use of literature citations. I think that you should state shortly and precisely what you want to assert from the results of this review. Overall, we believe that the authors over-explain the contents of the cited references.

Table 1. Although the table is organized in an easy-to-read manner, please consider creating a table that includes previous reports and results from other regions to determine if the results are appropriately compared or discussed.

Table 2. It is unclear what the criteria are for the type of rules.

The description of the discussion items is polite and clear, but is it possible to separate the items to make them more readable?

The reviewer has studied several reports of genetic testing of bacterial isolates, and it is not particularly rare to find such a heterogeneous population of isolates in a single institution's study?

Reviewer #2 (Comments for the Author):

Would be interesting to know if clinical outcomes changed after 2013 when transition from NDM-1 to NDM -5/-7.

Staff Comments:

Preparing Revision Guidelines

To submit your modified manuscript, log onto the eJP submission site at https://spectrum.msubmit.net/cgi-bin/main.plex. Go to Author Tasks and click the appropriate manuscript title to begin the revision process. The information that you entered when you first submitted the paper will be displayed. Please update the information as necessary. Here are a few examples of required updates that authors must address:

- Point-by-point responses to the issues raised by the reviewers in a file named "Response to Reviewers," NOT IN YOUR COVER LETTER.
- Upload a compare copy of the manuscript (without figures) as a "Marked-Up Manuscript" file.
- Each figure must be uploaded as a separate file, and any multipanel figures must be assembled into one file.
- Manuscript: A .DOC version of the revised manuscript
- Figures: Editable, high-resolution, individual figure files are required at revision, TIFF or EPS files are preferred

For complete guidelines on revision requirements, please see the journal Submission and Review Process requirements at https://journals.asm.org/journal/Spectrum/submission-review-process. **Submissions of a paper that does not conform to Microbiology Spectrum guidelines will delay acceptance of your manuscript.** "

Please return the manuscript within 60 days; if you cannot complete the modification within this time period, please contact me. If you do not wish to modify the manuscript and prefer to submit it to another journal, please notify me of your decision immediately so that the manuscript may be formally withdrawn from consideration by Microbiology Spectrum.

If your manuscript is accepted for publication, you will be contacted separately about payment when the proofs are issued; please follow the instructions in that e-mail. Arrangements for payment must be made before your article is published. For a complete list of **Publication Fees**, including supplemental material costs, please visit our website.

Corresponding authors may join or renew ASM membership to obtain discounts on publication fees. Need to upgrade your membership level? Please contact Customer Service at Service@asmusa.org.

Thank you for submitting your paper to Microbiology Spectrum.

Reply to Editor's comments

Reviewer #1

The fact that a long-term study of ExPECs was conducted on newborns admitted to the NICU is valuable information. Although the study was conducted in a single region, the content of the study was substantial, and I believe it will contribute to future research activities. On the other hand, I cannot find any evidence that the understanding of the transition of resistant strains itself will change the current practice of antimicrobial chemotherapy. In order to understand that the emergence of resistant strains is a critical situation, it is necessary to analyze the relationship between detected bacteria or isolates and outcomes (e.g., death, prolonged hospital stay, etc.). I have attached a comment on how. Please refer to the reference.

1. Executive Summary

There is no information on the source of the isolates considered in this study (e.g., information about the population, geographic region, etc.).

Answer: Isolates were collected primarily from the blood of septicaemic neonates admitted to a tertiary care hospital (IPGME&R and SSKM hospital of Kolkata, India). This tertiary care hospital in Kolkata, West Bengal caters to a population in Kolkata and also patients from different districts (at a distance of 100 km radius from Kolkata) of West Bengal.

2. L93 "This versatility is observed in its genome and also in its function or potential to cause disease" A reference to this statement is needed.

Answer: Authors have included the reference in reference number 9.

3. L106 What is "[WHO]"?

Answer:

Authors have expanded the term "WHO" as World Health Organization on Page No. 6 & Line No. 104 in the Basu_S_Marked Up Manuscript.

4. L171 "Whole genome sequencing (WGS)" WGS is spelled out in the sentence. The description of the method is redundant. It is too long compared to other items and should be shortened or moved to a supplement file.

Answer:

This is the sub-heading for the following section, hence it is not spelled out.

The authors have shortened this section in the revised manuscript (Basu_S_Marked-Up Manuscript) and moved part of it to the Supplementary file under the "Method for whole genome sequence (WGS) analysis" subheading.

5. Result.

L272 "Seventy *E. coli* were identified from the blood of septicaemic neonates (2009 to 2019)." The number of cases, patient background, and outcomes (treatment outcomes) are unknown. Also, whether the results are similar to other parts of India or unique to this facility needs to be added to the discussion.

Answer: A separate table (**Table 4**) depicting the association of outcome related to clinical and bacterial factors of neonates have been presented in the manuscript.

Two supplementary tables (**Supplementary Table S2A**, **S2B**) highlighting studies on *E. coli* causing neonatal sepsis from different parts of India and across the globe have been incorporated. Authors have compared data from these studies wherever applicable.

6. L231 "Isolates were resistant to second (52/80, 65%) and third-generation cephalosporins (67/80, 84%)" In the Methods section, the study on cephalosporins I am aware that the study regarding cephalosporins is not explicitly mentioned in the Methods section.

Answer: Antibiotic susceptibility pattern was determined for cephalosporins (cefoxitin, cefuroxime as 2nd gen and cefotaxime, ceftriaxone as 3rd gen cephalosporins) as a part of the antibiotic susceptibility test [disk diffusion data of cefoxitin, cefotaxime (2009-2017) and cefuroxime, ceftriaxone in VITEK®2 AST 280 (2018-2019]. This has been clarified in the foot note of **Table 1** (**Page No. 32 & Line No. 759**).

7. L267 "Transmissibility of metallo-β-lactamases and plasmid profile:" Is a colon necessary? **Answer:** Authors have now omitted the colon.

8. Discussion

L434 "under-5 mortality" The phrase "under-five" is also mentioned.

Answer: Authors have rephrased the term "under-5 mortality" by "under-five mortality" on **Page No. 20 & Line No 444-445.**

9. L480-489 "Several studies have shown that commensal E. coli are " The sentence is redundant due to the extensive use of literature citations. I think that you should state shortly and precisely what you want to assert from the results of this review. Overall, we believe that the authors over-explain the contents of the cited references.

Answer: Authors have modified the part of the discussion, taking into consideration comments from the reviewer.

10. Table 1. Although the table is organized in an easy-to-read manner, please consider creating a table that includes previous reports and results from other regions to determine if the results are appropriately compared or discussed.

Answer: Authors have included supplementary Table S2A and S2B in supplementary file representing list of published literature from different regions of India (S2A) and other countries (S2B) focusing on neonatal sepsis.

11. Table 2. It is unclear what the criteria are for the type of rules.

Answer: Authors have now modified Table 2.

12. The description of the discussion items is polite and clear, but is it possible to separate the items to make them more readable?

Answer: Authors have now modified the discussion.

13. The reviewer has studied several reports of genetic testing of bacterial isolates, and it is not particularly rare to find such a heterogeneous population of isolates in a single institution's study?

Answer: Yes, the authors agree to this comment. However, since this unit had a heterogeneous population of isolates, hence it is mentioned in the study.

14. Reviewer #2:

Would be interesting to know if clinical outcomes changed after 2013 when transition from NDM-1 to NDM -5/-7.

Answer: A descriptive table with patient data and outcomes has been incorporated (**Table 4**) in the main manuscript. The possible relationship between mortality and sepsis due to a $bla_{\text{NDM}}^{\text{+ve}}$ isolate was tested (**Supplementary Table S3B**) but not found to be statistically significant. It was noted that mortality increased from 2013 onwards (before 2013-39%, after 2013-57%). This has been incorporated on **Page No. 19 & Line No 432-433.**

Note:

New sequence types have been obtained for two study isolates which have been included in Table 1, Table 2, Figure 1 and Supplementary Figure 1.

May 27, 2023

Dr. Sulagna Basu National institute of Cholera and Enteric Diseases Bacteriology P33, CIT Road, Scheme XM, Beliaghata Kolkata, West Bengal 700010 India

Re: Spectrum05215-22R1 (A Decade-long Evaluation of Neonatal Septicaemic Escherichia coli: Clonal Lineages, Genomes and New Delhi Metallo-β-Lactamase Variants)

Dear Dr. Sulagna Basu:

Your manuscript has been accepted, and I am forwarding it to the ASM Journals Department for publication. You will be notified when your proofs are ready to be viewed.

The ASM Journals program strives for constant improvement in our submission and publication process. Please tell us how we can improve your experience by taking this quick <u>Author Survey</u>.

Publication Fees: We have partnered with Copyright Clearance Center to collect author charges. You will soon receive a message from no-reply@copyright.com with further instructions. For questions related to paying charges through RightsLink, please contact Copyright Clearance Center by email at ASM_Support@copyright.com or toll free at +1.877.622.5543. Hours of operation: 24 hours per day, 7 days per week. Copyright Clearance Center makes every attempt to respond to all emails within 24 hours. For a complete list of **Publication Fees**, including supplemental material costs, please visit our website.

ASM policy requires that data be available to the public upon online posting of the article, so please verify all links to sequence records, if present, and make sure that each number retrieves the full record of the data. If a new accession number is not linked or a link is broken, provide production staff with the correct URL for the record. If the accession numbers for new data are not publicly accessible before the expected online posting of the article, publication of your article may be delayed; please contact the ASM production staff immediately with the expected release date.

Corresponding authors may join or renew ASM membership to obtain discounts on publication fees. Need to upgrade your membership level? Please contact Customer Service at Service@asmusa.org.

Thank you for submitting your paper to Spectrum.

Sincerely,

Krisztina Papp-Wallace Editor, Microbiology Spectrum

Journals Department American Society for Microbiology 1752 N St., NW Washington, DC 20036 E-mail: spectrum@asmusa.org